Minerva Neurosciences Hits An All Time High After A Positive Deve
Minerva Neurosciences Inc. (NASDAQ: NERV) shares soared as much as 40% and hit a new high of $10 after the company announced that the resultsMonday from a Primomed non-human primate study, which showed that treatment with an analog of MIN-301, the company’s investigational neuregulin-1 compound, has resulted in improvements in a range of symptoms associated with…